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BACKGROUND & AIMS: Persistent activation of the inflamma-
tory response contributes to the development of inflammatory
bowel diseases, which increase the risk of colorectal cancer. We
aimed to identify microRNAs that regulate inflammation during
the development of ulcerative colitis (UC) and progression to
colitis-associated colon cancer (CAC). METHODS: We performed
a quantitative polymerase chain reaction analysis to measure
microRNAs in 401 colon specimens from patients with UC,
Crohn’s disease, irritable bowel syndrome, sporadic colorectal
cancer, or CAC, as well as subjects without these disorders
(controls); levels were correlated with clinical features and dis-
ease activity of patients. Colitis was induced in mice by admin-
istration of dextran sodium sulfate (DSS), and carcinogenesis was
induced by addition of azoxymethane; some mice also were given
an inhibitor of microRNA214 (miR214). RESULTS: A high-
throughput functional screen of the human microRNAome
found that miR214 regulated the activity of nuclear factor-kB.
Higher levels of miR214 were detected in colon tissues from
patients with active UC or CAC than from patients with other
disorders or controls and correlated with disease progression.
Bioinformatic and genome-wide profile analyses showed that
miR214 activates an inflammatory response and is amplified
through a feedback loop circuit mediated by phosphatase and
tensin homolog (PTEN) and PDZ and LIM domain 2 (PDLIM2).
Interleukin-6 induced signal transducer and activator of tran-
scription 3 (STAT3)-mediated transcription of miR214. A miR214
chemical inhibitor blocked this circuit and reduced the severity of
DSS-induced colitis in mice, as well as the number and size of
tumors that formed in mice given azoxymethane and DSS. In
fresh colonic biopsy specimens from patients with active UC, the
miR214 inhibitor reduced inflammation by increasing levels of
PDLIM2 and PTEN. CONCLUSIONS: Interleukin-6 up-regulates
STAT3-mediated transcription of miR214 in colon tissues, which
reduces levels of PDLIM2 and PTEN, increases phosphorylation of
AKT, and activates nuclear factor-kB. The activity of this circuit
correlateswithdisease activity inpatientswithUCandprogression
to colorectal cancer.Keywords: IL6; IBD Progression; Mouse Model; Chronic
Inflammation.
here is an increasing incidence of ulcerative colitisT(UC), potentially resulting from the Westernized
way of life, diet, and environmental alterations1,2; patients
with long-standing and extensive disease are at increased
risk of developing colorectal cancer.3–5 Although early
studies have shown standardized incidence ratios between
3.7% and 5.7%,3,4 the magnitude of this risk is unknown.
More recent studies have reported much lower rates most
likely related to improved therapeutic management.5–9
Practice guidelines recommend lifelong surveillance colo-
noscopies at intervals of 1–3 years, starting 8–10 years after
diagnosis.10 The rationale of surveillance colonoscopy is to
detect premalignant mucosal dysplasia. Patients with high-
grade dysplastic lesions are recommended to undergo pro-
phylactic proctocolectomy, whereas for low-grade dysplastic
lesions there is insufficient evidence to recommend sur-
gery.10 A medical decision analysis failed to show a benefit of
surveillance colonoscopy, and, presently, there are also no
clinical data to support the contention that surveillance
colonoscopy is a cost-effective means to prevent death
from colorectal cancer in UC patients.11 Improving sur-
veillance strategies with the use of molecular markers has
not yet been successful. Markers associated with the
dysplasia-cancer sequence have been reported, including
aneuploidy,12 p53,13 microsatel lite instability,14 and the




ATmucin-associated sialyl-Tn antigen,15 but none have yet been
recommended in surveillance management. Genome-wide
associated studies showed susceptibility loci and pathways
that influence the risk of disease,16,17 but alone are insuffi-
cient to determine specific causative relationships,18 sug-
gesting that other genetic and/or epigenetic alterations
contribute to UC pathogenesis.19
MicroRNAs are small noncoding RNAs, 18–25 nucleo-
tides in length, which regulate gene expression through
binding in 3’-untranslated regions of target messenger RNAs
(mRNAs).20 MicroRNAs are essential regulators of inflam-
matory signaling pathways,21,22 contributing to the patho-
genesis of different human inflammatory diseases,23–25
including IBD.26,27 Furthermore, manipulation in the
expression levels of microRNAs could suppress the inflam-
matory response,24 suggesting their therapeutic potential.
Although microRNA signaling pathways have been reported
to link chronic inflammation to malignant transformation in
breast cancer and liver cancer,24,28,29 such evidence for UC-
associated cancer currently is missing. We hypothesized
that microRNAs may contribute to the development of UC
and progression to colon cancer, while manipulation in the
expression levels of these microRNAs could have thera-
peutic potential in patients with premalignant lesions.
Materials and Methods
Study Oversight
The study was approved by the institutional review board
at each study center. All patients from whom tissue samples
were obtained at the University of California at Los Angeles
provided written informed consent. The patient samples were
obtained at the Leiden University Medical Center according to
the instructions and guidelines of the Leiden University Medical
Center Medical Ethics Committee and in accordance with the
Helsinki Declaration.
MicroRNA Library Screen
NCM460 immortalized epithelial cells were plated in
96-well plates and transfected with a microRNA inhibitor li-
brary consisting of 348 microRNA inhibitors and 2 negative
control microRNAs (100 nmol/L) (Dharmacon, Inc, Lafayette,
CO), as previously described.27 At 24 hours after transfection,
the cells were treated with interleukin (IL)6 for 24 hours, and
the phosphorylation of nuclear factor-kB (NF-kB) was assessed
by Phospho-RelA/NF-kB p65 (S536) Cell-Based Enzyme-Linked
Immunoassay (KCB7226; R&D Systems, Minneapolis, MN).
MicroRNA inhibitors that affected more than 50% of the
phosphorylation of NF-kB were considered positive hits.
Statistical Analysis
All experiments were performed in triplicate unless other-
wise stated. Statistical analyses were performed with the use of
Origin software (version 8.6) (Origin Lab, Northampton, MA)
and the SAS statistical package (version 9.4) (SAS, Cary, NC). The
Student t test was used to examine the statistical difference in
microRNA (miR)-214 expression between control colonic tis-
sues and specimens derived from different intestinal pathol-
ogies, between active and inactive UC specimens, between UCspecimens categorized based on disease duration, and between
the differentially treated cells and mice groups. The Krus-
kall–Wallis test and the post hoc Wilcoxon 2-sample test with
Bonferroni significance level adjustment for multiple testing
were used for age comparisons, chi-square test was used for sex
comparisons, and the Fisher exact test was used for tumor stage
comparison. The correlation significance was determined by
means of Spearman and Pearson correlation analyses. A P value
of .05 or less was considered to indicate statistical significance.
Additional information is available in the Supplementary
Materials and Methods section.Results
High-Throughput Inhibition of the Human
MicroRNAome in Human Colonocytes Shows
Novel Regulators of NF-kB Activity
UC development is characterized by activation of in-
flammatory pathways, including NF-kB signaling. To identify
microRNAs that regulate the NF-kB activity in human colo-
nocytes, we performed a microRNA functional screen by
targeting the human microRNAome in IL6-treated NCM-460
colonic epithelial cells (Figure 1A). In the primary screen,
we found 9 microRNA inhibitors to regulate NF-kB
phosphorylation levels by more than 50% (P < 0.05).
Specifically, we found 2 microRNA inhibitors (miR-26b and
miR-199a) that induced NF-kB phosphorylation levels
significantly, and 7 inhibitors (miR-7, miR-146a, miR-373,
miR-372, miR-181b, miR-21, and miR-214) suppressed
NF-kB phosphorylation levels (Figure 1B). Among these
inhibitors, previous studies have shown that miR-21,
miR-181b, and miR-146a are essential regulators of the
inflammatory response, validating our functional screen
assay.22,30 Interestingly, our screen showed that the inhib-
itor against miR-214 was the most efficient (>90%) sup-
pressor of NF-kB phosphorylation, whereas the inhibitor
against miR-199a was the most efficient (>90%) activator
of NF-kB phosphorylation in human colonocytes.MiR-214 Is Specifically Overexpressed in UC
Colonic Tissues
According to our microRNA inhibitor screen data, in
human colonocytes 7 microRNA inhibitors have the ability
to suppress the inflammatory response significantly. Next,
our aim was to evaluate the clinical relevance of these
in vitro findings and to assess the expression levels of these
microRNAs in human colonic tissues derived from UC and
CD patients and control subjects (Figure 1C). Real-time
polymerase chain reaction (PCR) analysis showed that
miR-21 and miR-146a expression is increased in both UC
and CD colonic tissues relative to controls, consistent with
previous studies.31 On the other hand, miR-7, miR-181b,
miR-372, and miR-373 were not significantly deregulated in
UC or CD relative to control subjects. Interestingly, we found
that miR-214 is highly (>8-fold) up-regulated specifically in
UC colonic tissues relative to control subjects and CD patient
tissues. To further validate these findings in a large number
of patient samples, we examined miR-214 levels in UC
Figure 1. High-content inhibitor screening identifies microRNAs that control NF-kB in ulcerative colitis. (A) Screening workflow:
a library of 348 microRNA inhibitors was transfected in colonic epithelial cells in triplicate and the activation of NF-kB was
measured after treatment with IL6. (B) Screen data plotted as absolute levels (x-axis) of phosphorylated NF-kB (on S536),
compared with scrambled sequence controls (no effect, value ¼ 1.34) and P value from Student t test (y-axis). Box shows
microRNA inhibitors that affect NF-kB phosphorylation by more than 50%. (C and D) MiR-214 is overexpressed specifically in
colonic tissues from patients with UC. (C) MicroRNAs involved in the activation of NF-kB were quantified in colonic specimens
by quantitative real-time PCR. (D) MiR-214 is overexpressed in colonic tissues from patients with UC from 3 different patient
cohorts, as assessed by qPCR. IBS, irritable bowel syndrome; Data are represented as means ± SE. ***P < .001, **P < .01 in
comparison with control; #P< .001, in comparison with UC, Student t test. (E) MiR-214 is up-regulated in the colonic epithelium
of human active UC samples. In situ hybridization indicates the expression of miR-214 (blue) in the colonic epithelium of UC and
control subjects. Nuclear Red was used as a counterstain. Scale bars: 50 mm. (F) MiR-214 expression correlates with UC
activity. Data are represented as means ± SE. ***P < .001, in comparison with UC patients in remission, Student t test.













AT(n ¼ 120) and control (n ¼ 107) colonic tissues from 3
different cohorts (Supplementary Tables 1 and 2). Consis-
tent with our initial findings, miR-214 levels were found to
be increased significantly in UC, but not in irritable bowel
syndrome (n ¼ 22) or Crohn’s disease (CD) (n ¼ 60)
(Figure 1D). In situ hybridization in human colonic tissues
identified epithelial cells as the origin of miR-214 over-
expression (Figure 1E and Supplementary Figure 1).
MiR-214 Expression Correlates With UC
Disease Activity
To evaluate the clinical relevance of our findings, we
examined miR-214 expression in correlation with dif-
ferent clinicopathologic parameters. MiR-214 levels weresignificantly higher in UC patients with active disease rela-
tive to patients in remission (Figure 1F), but did not differ in
relation to UC patient sex or anatomic site, or to sex/disease
location in CD patients (Supplementary Figure 2). Taken
together, these results show that MIR214 is an epithelial-
expressed gene that regulates NF-kB activity and is
deregulated specifically in UC in correlation with disease
activity.
Integration of Computational and Molecular
Analyses for Identification of miR-214
Downstream Targets in Colitis
To establish the molecular link between miR-214 and
UC development, we aimed to identify downstream gene
Figure 2.MiR-214 targets PDLIM2 and PTEN and activates NF-kB in the colonic epithelium. (A) Strategy for the identification
and validation of miR-214 targets regulating NF-kB. MiR-214 targets predicted by 4 different types of software (n ¼ 280). Gene
expression analysis validated 71 miR-214 direct targets inhibited by more than 50% (**P < .01). Targets were sorted based on
relation to the NF-kB pathway and alignment of the 3’UTR of mRNAs and the miR-214 sequence. (B) MiR-214 targets the 3’UTR
of PDLIM2 and PTEN mRNAs. Luciferase assays performed in a second colonic epithelial cell line, NCM460, showed significant
inhibition of the 3’UTR reporter activities by miR-214. Data are shown as the means ± SE. ***P < .001, **P < .01, in comparison
with untreated and control (scramble) miR-treated cells, Student t test. (C) MiR-214 regulates the mRNA levels of PDLIM2 and
PTEN in colonic epithelial cells. Effect of miR-214 on the expression of PDLIM2 and PTEN in NCM460 cells, as assessed by
qPCR. Data are shown as the means ± SE. **P < .01, in comparison with untreated and control (scramble) miR-treated cells,
Student t test. (D) MiR-214 regulates the protein levels of PDLIM2 and PTEN in colonic epithelial cells. Western blot analysis of
PDLIM2 and PTEN protein levels in NCM356 from 3 independent replicates. a-Tubulin was used as loading control. (E) MiR-214
regulates the phosphorylation of NF-kB on S536. Data are shown as the means ± SE of phosphorylated nuclear factor-kB (on
S536) levels, as assessed by ELISA. **P < .01, in comparison with untreated and control (scramble) miR-treated cells, Student t
test. (F) PDLIM2 (P < .01) and PTEN (P < .05, Student t test) expression is down-regulated in colonic tissues from UC patients.




ATtargets that could mediate NF-kB activation in human
colonocytes. We developed an innovative strategy, con-
sisting of 5 different steps, to identify the key effectors of
miR-214 activity in UC (Figure 2A). Specifically, during the
first step we used 4 different types of microRNA target
prediction software and identified 280 common miR-214
gene targets based on their sequence complementarity.
The second step was to analyze the expression of the
genes regulated by miR-214 overexpression in human
colonocytes, by performing high-throughput expression
analysis. This analysis showed a signature of 71 genes
(Supplementary Table 3) that were expressed differen-
tially (expression, <50%; P < .01) in miR-214–treated
NCM460 colonocytes. The next steps included evaluation
of these 71 genes for their correlation with the NF-kB
signaling pathway and direct interaction with miR-214
using 3’ untranslated region (3’UTR) luciferase assays.
Finally, these direct interactions between miR-214 and itstarget genes were validated in a second colonic epithelial
cell line.PDZ and LIM Domain 2 and Phosphatase and
Tensin Homolog Are Direct Downstream
Effectors of miR-214 in UC
The comprehensive analysis described earlier showed 2
genes that fulfill all the criteria as direct targets of miR-214
in UC. Specifically, PDZ and LIM domain 2 (PDLIM2) and
phosphatase and tensin homolog (PTEN) were found to be
expressed differentially in miR-214–overexpressing colo-
nocytes, possessing target sequences for miR-214 in their
3’UTRs (Figure 2A). PDLIM2 is a nuclear ubiquitin E3
ligase and a known inhibitor of NF-kB activity,32 and PTEN
is a suppressor of the AKT signaling pathway33 shown to
intervene with NF-kB activation34,35 and result in
increased severity of colitis.36 To validate the direct
October 2015 MicroRNA for Colitis and Colon Cancer 985interactions at the molecular level between miR-214 and
PTEN or PDLIM2, we performed luciferase assays. Specif-
ically, miR-214 was overexpressed in cells together with a
luciferase vector harboring the 3’UTR of PTEN or PDLIM2
mRNAs. This analysis showed that miR-214 over-
expression inhibited both PTEN and PDLIM2 3’UTR lucif-
erase activities (Figure 2B). Furthermore, miR-214
overexpression suppressed PTEN and PDLIM2 mRNA
(Figure 2C) and protein levels (Figure 2D). In addition,
overexpression of miR-214 induced NF-kB (s536) phos-
phorylation (Figure 2E) and subsequently the expression
of IL6 (Supplementary Figure 3), indicating that PTEN and
PDLIM2 are direct downstream effectors of miR-214
involved in the regulation of the NF-kB inflammatory
response. Finally, in reflection of the human relevance of
these findings, PTEN and PDLIM2 mRNA levels wereFigure 3.MiR-214 activates an inflammatory feedback loop cir
transcriptionally activate miR-214 through STAT3. (A) The Lever
binding site on the promoter of the MIR214 gene (upper panel)
promoter of the MIR214 gene, as assessed by chromatin im
expression of miR-214, as assessed by qPCR (right panel). Da
with untreated cells, Student t test. (B) STAT3 binding on the
MIR214 gene. IL6 induces the luciferase activity of the wild-typ
STAT3 binding site abolishes promoter activation by IL6. M, mu
***P < .001 in comparison with untreated cells; #P < .001 in co
suppresses PDLIM2 and PTEN expression in colonocytes thr
PDLIM2 and PTEN suppression, as assessed by qPCR. Data
with untreated cells; @P < .01 in comparison with negative c
representation of the proposed model. (E and F) Activation
(E) miR-214 overexpression activates STAT3 while silencing o
Western blot analysis of PDLIM2 and PTEN protein levels and
cells. a-Tubulin was used as loading control. (F) Pharmacolog
pression of PDLIM2 and PTEN, as assessed by qPCR. Data are
comparison with IL6-treated cells, Student t test.decreased in UC colonic tissues relative to controls
(Figure 2F).STAT3 Transcription Factor Regulates miR-214
Expression in Human Colonocytes
Given that miR-214 is up-regulated significantly in
UC, we were interested to identify the molecular mecha-
nisms that regulate miR-214 expression. We performed
a bioinformatics analysis using the Lever/PhylCRM algo-
rithm, which predicts highly conserved binding sites in
promoter areas of genes.37 This algorithm predicted that the
strongest conserved binding site in the MIR214 promoter
area is for the transcription factor STAT3 (Figure 3A). To
validate this prediction at the molecular level we performed
a dual experimental approach. First, we performedcuit in the colonic epithelium. (A and B) Inflammatory signals
and PhylCRM algorithms showed the presence of the STAT3
. IL6 dose-dependently induces the binding of STAT3 on the
munoprecipitation and qPCR analysis (left panel), and the
ta are shown as the means ± SE. ***P < .001 in comparison
promoter is required for the transcriptional activation of the
e (WT) MIR214 gene promoter, whereas mutagenesis of the
tated STAT3 binding site. Data are shown as the means ± SE.
mparison with the IL6-induced WT promoter activity. (C) IL6
ough miR-214. Effect of miR-214 inhibition on IL6-induced
are shown as the means ± SE. ***P < .001 in comparison
ontrol (NC) miR-treated cells, Student t test. (D) Schematic
and inhibition of the inflammatory feedback loop circuit.
f miR-214 abrogates the IL6-induced activation of STAT3.
the phosphorylation levels of STAT3 and NF-kB in NCM356
ic inhibition of Akt or NF-kB reverses the IL6-induced sup-


















ATchromatin immunoprecipitation analysis by using an anti-
body against STAT3 and performed quantitative PCR (qPCR)
upon stimulation with IL6, using primers specific for the
MIR214 promoter area. This experiment showed that STAT3
binds directly, in an IL6 dose-response rate, on the MIR214
promoter. In agreement, qPCR analysis showed the IL6
dose-dependent induction of miR-214 expression
(Figure 3A). In the second approach, the miR-214 promoter
area was cloned in a reporter vector upstream of the lucif-
erase gene. We found that IL6 induced MIR214 promoter
activity in a dose-dependent manner, an effect abolished by
mutation of the STAT3 binding site (Figure 3B).
MiR-214 Is Part of a Feedback Loop Circuit
Mediated by PDLIM2 and PTEN Genes
The role of miR-214 as an inflammatory mediator
through the regulation of PDLIM2 and PTEN was studied in
NCM356 human colonocytes. IL6 dose-dependently sup-
pressed PDLIM2 and PTEN mRNA levels, an effect reversed
by the inhibition of miR-214 (Figure 3C). In accord, Akt
phosphorylation was increased upon IL6 treatment, and
reduced by miR-214 inhibition (Supplementary Figure 4).
These findings suggest that IL6 induces miR-214 through
STAT3-mediated transcriptional activation, creating a posi-
tive feedback loop circuit (Figure 3D). Specifically, miR-214
overexpression directly suppresses the expression levels of
PTEN and PDLIM2 genes. The suppression of PDLIM2 re-
sults in direct activation of NF-kB, whereas the suppression
of PTEN results in the activation of the AKT kinase,
contributing to the phosphorylation of NF-kB. In turn, the
NF-kB transcription factor induces IL6 expression and thus
activates the STAT3 transcription factor, which binds
directly on the MIR214 gene promoter area, re-enforcing its
up-regulation. To assess the activity of the feedback loop
circuit we either overexpressed the microRNA or treated
cells with IL6 in combination with miR-214 silencing.
Western blot analysis of cell lysates collected 96 hours later
showed the sustained suppression of PTEN and PDLIM2 and
increased phosphorylation of NF-kB and STAT3 upon miR-
214 overexpression or treatment with IL6. Importantly,
miR-214 targeting reversed the effects of IL6, in support of
the dependence of circuit activation on miR-214 (Figure 3E).
Along the same line, pharmacologic inhibition of Akt or
NF-kB resulted in partial or complete reversal, respectively,
of the IL6-induced effects on PTEN and PDLIM2 expression
(Figure 3F).
Effects of a miR-214 Chemical Inhibitor on UC
Ex Vivo and In Vivo
To evaluate the therapeutic potential of miR-214 inhi-
bition in UC through regulation of the feedback loop cir-
cuit, we used a chemically stable inhibitor that was highly
efficient in suppressing miR-214 in human colonocytes
in vitro (Figure 4A). We studied the effects of the miR-214
chemical inhibitor ex vivo on freshly isolated colonic
biopsy specimens from UC patients with active disease
(Figure 4B). The inhibitor efficiently inhibited miR-214 in
the colonic explants (Figure 4C), and suppressed theinflammatory response by increasing the expression of
both PDLIM2 and PTEN in colonic explants from 3 UC
patients with active disease (Figure 4D). In addition to the
ex vivo findings, we examined the effects of the miR-214
inhibitor on experimental colitis in mice. Mice treated
with dextran sulfate sodium (DSS) and the miR-214 in-
hibitor and colitis disease activity was evaluated by using
different parameters (Figure 4E). Importantly, we found
that the miR-214 inhibitor reduced disease activity in DSS-
induced experimental colitis (Figure 4F). Taken together,
these in vitro, in vivo, and ex vivo data suggest the ther-
apeutic potential of the miR-214 inhibitor in UC patients
with active disease.
MiR-214 Is Overexpressed in Long-Lasting
Colitis and Colitis-Associated Colon Cancer
Although the association between UC and colorectal
cancer was documented as early as 1925,38 its molecular
biology remains to be explored. We questioned the role of
miR-214 during the transition from UC to cancer. Interest-
ingly, we found that miR-214 is up-regulated in mice with
chronic but not acute inflammation induced by DSS
(Figure 5A). In the same line, colonic tissues from patients
with long-standing (>10 years) UC have increased miR-214
levels compared with colonic tissues from patients with
UC for fewer than 10 years (Figure 5B), suggesting
that miR-214 may provide a link between UC and
colorectal cancer development. Notably, miR-214 levels do
not change significantly in colonic tissues of 2,4,6-
trinitrobenzenesulfonic acid–treated mice as well as in
polyps formed in the adenomatous polyposis coli mutant
(APCmin) mouse model (Supplementary Figure 5). Therefore,
we compared miR-214 levels by qPCR and in situ hybridi-
zation in tumors from colitis-associated colon cancer (CAC)
and sporadic colon cancer (CRC) patients. This analysis
showed a dramatic overexpression of miR-214 in CAC, but
no difference between CRC and controls (Figure 5C and D
and Supplementary Figure 6). Overall, these findings sug-
gest that miR-214 is increased during UC development
and amplified during progression to colorectal cancer.
MiR-214 as a Novel Oncogene in Colon Cancer
To examine the significance of miR-214 in colorectal
oncogenesis we performed gain-of-function and loss-of-
function studies. Overexpression of miR-214 induced
the colony formation ability (Figure 6A and Supplementary
Figure 7A) and invasiveness (Figure 6B and Supplementary
Figure 7B) of human colon cancer cells, suggesting its
oncogenic role. On the other hand, silencing of miR-214
suppressed the IL6-induced tumorigenic and invasive
phenotype, pointing to the dependence of IL6 tumorigenic
effects on miR-214. Next, we investigated whether
miR-214 acts through regulation of the feedback loop cir-
cuit. We found that IL6 up-regulated miR-214 in HCT-116,
HT-29, LoVo, and DLD-1 colon cancer cells (Figure 6C),
mediated by the direct binding of STAT3 on MIR214 pro-
moter area (Figure 6C and D). Furthermore, IL6-induced
miR-214 expression resulted in PDLIM2 and PTEN
Figure 4. A chemical inhibitor reverses the effects of miR-214 on colonic tissues from UC patients and ameliorates disease
activity in a mouse colitis model. (A) A chemical inhibitor effectively suppresses miR-214 expression in colonocytes in vitro.
The effectiveness of a miR-214–specific chemical inhibitor was tested in vitro on NCM356 colonocytes. Cells treated with
the miR-214 chemical inhibitor (for 30 minutes) were analyzed 24 hours later for miR-214 levels, as assessed by qPCR. Data
are shown as the means ± SE. ***P < .001 in comparison with untreated and negative control–treated cells, Student t test.
(B) Fresh colonic biopsy specimens isolated at colonoscopy were divided in 2 and treated with the chemical inhibitor
against miR-214 or negative control (NC). (C) A chemical inhibitor effectively suppresses miR-214 expression in colonic
biopsy specimens ex vivo. After treatments, RNA was extracted from biopsy specimens and analyzed for miR-214 levels by
qPCR. Data are shown as the means ± SE. ***P < .001 in comparison with untreated and negative control–treated biopsy
specimens, Student t test. (D) A chemical inhibitor reverses miR-214 effects in colonic biopsy specimens ex vivo. Biopsy
specimens were analyzed for PDLIM2 and PTEN levels by qPCR. (E) The therapeutic protocol applied on the chronic DSS
mouse model and the criteria used for assessment of the disease activity score. miR-214 inhibitor or the negative control
were administered intracolonically in DSS-treated mice after day 8 for 4 cycles (every 2 days). On day 20, the mice were
killed, and colon length was measured. (F) A chemical inhibitor of miR-214 ameliorates disease activity in the chronic DSS
mouse colitis model. Data are shown as the means ± SE. **P < .01 in comparison with untreated and NC-treated DSS mice,
4 mice per group, Student t test.













ATsuppression (Supplementary Figure 8), Akt phosphoryla-
tion (Supplementary Figure 9), and NF-kB activation
(Supplementary Figure 10), indicating that the miR-214
feedback loop circuit is hyperactivated duringoncogenesis. MiR-214 overexpression suppressed PTEN
and PDLIM2 mRNA levels (Supplementary Figure 11), and
in support of the human relevance, PDLIM2 and PTEN
levels were decreased significantly in tumors from CAC
Figure 5.MiR-214 expression correlates with the duration
of ulcerative colitis and the development of colitis-
associated cancer. (A) Chronic colonic inflammation regu-
lates miR-214 expression in mice. Data are shown as the
means ± SE. ***P < .001 in comparison with control
(DSS-untreated) mice. (B) Chronic colonic inflammation
regulates miR-214 expression in UC patients. Data are
shown as the means ± SE. **P < .01, ***P < .001 in com-
parison with control (no UC) tissues. (C) miR-214 is hyper-
expressed in CAC, but not sporadic CRC, as shown by
qPCR. Data are shown as the means ± SE. ***P < .001 in
comparison with control tissues; #P < .001 in comparison
with CAC, Student t test. (D) In situ hybridization indicates
the overexpression of miR-214 (blue) in tumors from CAC
compared with CRC patients. Nuclear Red was used as
counterstain. Scale bars: 50 mm.




ATpatients relative to controls (Supplementary Figure 12). In
contrast, their levels were not decreased significantly in
tumors from CRC patients, supporting the specificity of the
miR-214 circuit in CAC (Figure 6E). Given that miR-214
increases cancer cell aggressiveness, we examined the
miR-214 correlation to colon cancer progression. Exami-
nation of human tumors indicated that miR-214 specif-
ically is up-regulated during CAC disease progression
(Figure 6F), providing additional evidence of the specificity
of miR-214 circuit in UC and CAC.MiR-214 Chemical Inhibitor Suppresses
Azoxymethane-DSS–Induced Colon
Carcinogenesis
According to our data, the miR-214–positive feedback
loop circuit links chronic inflammation to colon carcino-
genesis. Therefore, targeting miR-214 may suppress the
development of CAC. We applied a therapeutic protocol
consisting of intracolonic administration of a chemicalmiR-214 inhibitor or microRNA-negative control for 4 cy-
cles, weekly (Figure 7A and Supplementary Figure 13) on
the azoxymethane-DSS mouse model. The miR-214 inhibitor
reduced the number (Figure 7B) and size (Figure 7C) of
tumors significantly. Mechanistically, the miR-214 inhibitor
suppressed tumor growth through the induction of
apoptosis and activation of caspase-3 (Figure 7D). In addi-
tion, immunohistochemical analysis showed that miR-214
inhibition reduced NF-kB and Akt phosphorylation levels,
indicating efficient suppression of the miR-214 molecular
circuit, and decreased the proliferation rate of colon cancer
cells (Figure 7E).Discussion
MiR-214 expression correlates with UC activity and
disease duration and provides the molecular rationale for
the current practice guidelines recommending surveillance
colonoscopy 8–10 years after diagnosis of UC.39 Although
the association between IBD and cancer, linking colonic
inflammation to colorectal cancer risk, was documented as
early as 1925,38 its molecular biology remains unknown. We
propose that a microRNA, miR-214, is the central regulator,
based on its unique expression pattern in ulcerative col-
itis–associated colon cancer patients. Our findings suggest
that miR-214 could serve as a biomarker identifying pa-
tients at risk for this malignant transformation. We also
show that miR-214 expression correlates well with disease
activity and disease duration, which offers the molecular
rationale for the current practice guidelines recommending
surveillance colonoscopy for UC patients 8–10 years after
diagnosis.39
Clinical and epidemiologic studies have shown a strong
association between chronic inflammation and the devel-
opment of cancer through activation of inflammatory mol-
ecules.40,41 IL6 is secreted by epithelial and immune cells
contributing to the transformation of normal into malignant
cells.24,28,42 Although inflammatory responses have been
found to be activated in both sporadic and colitis-associated
colon cancers, it is not clear whether these inflammatory
signals regulate the same signaling pathways. Our data
show miR-214 as an inflammatory effector molecule that is
deregulated in colitis-associated colon cancer patients. The
STAT3 transcription factor is able to bind to the promoter
area of miR-214, and the presence of IL6 leads to
IL6-STAT3–dependent miR-214 expression and thus the
regulation of both the PDLIM2–NF-kB and the PTEN-Akt
pathways. In addition, miR-214 up-regulation induces the
NF-kB–IL6 pathway, suggesting the presence of a miR-214
feedback loop circuit. Gain-of-function and loss-of-function
assays confirmed the significance of miR-214 in colorectal
oncogenesis. Given that IL6-STAT3 signaling is activated
while miR-214 expression is not deregulated in other
gastrointestinal diseases, such as CD and CRC, we propose
that the responsiveness of the MIR214 gene to inflammatory
signals depends on epigenetic cues deregulated on sus-
tained chronic colonic inflammation. Although we identified
feedback loop inflammatory circuits in different human
Figure 6. Tumorigenic potential of the miR-214 circuit in human colonocytes. (A and B) IL6 through miR-214 regulates
the tumorigenic properties of colon cancer cells. (A) MiR-214 overexpression (pre–miR-214) enhances colon cancer cell
colony formation in soft agar, whereas miR-214 inhibition (as–miR-214) reverses the effects of IL6. Scale bars: 500 mm.
(B) MiR-214 overexpression (pre–miR-214) enhances colon cancer cell invasion in Matrigel (BD Biosciences, Franklin Lakes,
NJ), whereas miR-214 inhibition (as–miR-214) reverses the effects of IL6. Scale bars: 100 mm. Data are shown as the means ±
SE. **P < .01, ***P < .001 in comparison with untreated and control (pre–miR-C)-treated cells. #P < .001 in comparison with
as–miR-negative control (NC)-treated cells; Student t test. (C) IL6 dose-dependently induces the expression of miR-214 and
the binding of STAT3 on the promoter of the MIR214 gene, in colon cancer cells. Effects of IL6 on the expression of miR-214,
as assessed by qPCR and STAT3 binding, as assessed by chromatin immunoprecipitation and qPCR analysis. Data are shown
as the means ± SE. ***P < .001 in comparison with untreated cells, Student t test. (D) STAT3 binding on the promoter is
required for the transcriptional activation of the MIR214 gene in colon cancer cells. IL6 induces the luciferase activity of the
wild-type (WT) MIR214 gene promoter, whereas mutagenesis of the STAT3 binding site abolishes promoter activation by
IL6. M, mutated STAT3 binding site. Data are shown as the means ± SE. ***P < .001 in comparison with untreated
cells. #P < .001, @P < .01 in comparison with the IL6-induced WT promoter activity, Student t test. (E) PDLIM2 and
PTEN expression is suppressed significantly in CAC but not CRC, as assessed by qPCR. Data are shown as the means
± SE. **P < .01, ***P < .001 in comparison with control colonic tissues, Student t test. (F) MiR-214 levels correlate positively
with tumor staging in CAC. Data are shown as the means ± SE. *P < .05 in comparison with early CAC stages (I and II), Student
t test.














Figure 7. A chemical inhibitor
of miR-214 effectively sup-
presses colitis-associated
colorectal cancer in vivo. (A)
Protocol for anti–miR-214
therapy in the mouse azoxy-
methane (AOM)-DSS colitis-
associated colorectal cancer
model. (B–D) Evaluation of
the therapeutic potential
of intracolonic administration
of miR-214 inhibitor on the
(B) number and (C) size of
tumors, and (D) the levels
of cleaved caspase 3 in the
tumors formed in the
AOM-DSS mouse model of
colitis-associated colorectal
cancer. Data are shown as
the means ± SE. ***P < .001
in comparison with untreated
and control (miR–negative
control [NC] inhibitor)-
administered mice, 10 mice
per group, Student t test. (E)
H&E, pNF-kB (S536), pAkt
(S473), and Ki-67 staining in
sections of colonic tissues
from mice treated with the
chemical miR-214 inhibitor or
negative control. Scale bars:
200 mm (for H&E staining)
and 50 mm (for immunohis-
tochemistry). (F) Schematic
representation of the activity
and role of the miR-214
molecular circuit in UC and
CAC. In healthy noninflamed
colonic epithelial cells,
PDLIM2 and PTEN expres-
sion suppresses the activa-
tion of Akt and NF-kB. During
the development of UC, miR-
214 targets PDLIM2 and
PTEN to activate Akt and
NF-kB. In turn, NF-kB
regulates IL6 expression and
thus STAT3 activity. STAT3-
mediated transcriptional
activation of miR-214 creates
a positive feedback loop
circuit that is attenuated
when disease is in an inactive
state. In long-standing UC,
overexpression of miR-214
and hyperactivation of this
inflammatory circuit pro-
motes the development of
colorectal cancer.





October 2015 MicroRNA for Colitis and Colon Cancer 991diseases,24,28 we show a feedback loop mechanism that is
involved not only in 2 human diseases (ulcerative colitis and
colon cancer), but, importantly, acts as a rheostat, being
hyperactivated and contributing to the progression from
colitis to colon cancer (Figure 7F).
Therapeutic applications are conceivable as shown in
our experiments by using the novel miR-214 chemical in-
hibitor. Studies have shown these microRNA mimics or
microRNA inhibitors have a therapeutic potential in
different types of cancer and autoimmune diseases. With the
recent demonstration that inhibition of miR-122 reduces
viral load in HCV-infected chimpanzees,43 miR-122 in-
hibitors are already in phase II trials. We recently showed
that intravenous administration of a microRNA mimic could
have therapeutic potential in liver cancer patients through
suppression of the inflammatory response.24 Here, we
showed that intracolonic administration of chemically
modified antisense–miR-214 suppresses the development of
tumor growth effectively in an animal model of colitis-
associated colon cancer, suggesting that a similar
approach could be considered for colitis-associated
dysplasia and cancer.T
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
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Supplementary Materials and Methods
Materials
Human colon cancer cell lines (American Type Culture
Collection, Manassas, VA) were cultured under standard
culture conditions, and NCM356 and NCM460 were grown in
M3:10 (INCELL, San Antonio, TX). IL6 (200-06; Peprotech,
Rocky Hill, NJ) was used to stimulate cells, whereas MK2206
(S1078) andBAY11-7082 (S2913; Selleckchem,Houston, TX)
were used to inhibit Akt and NF-kB, respectively. Antibodies
used in Western blot analyses were phospho–NF-kB p65
(Ser536) (3033), phospho-STAT3 (Tyr705) (9145), NF-kB
p65 (8242), STAT3 (9139), PDLIM2 (8144), PTEN (9188; Cell
Signaling Technology), and a-tubulin (T5168; Sigma, St.
Louis, MO).
Bioinformatic Analysis
The Lever and PhylCRM algorithms have been used to
identify STAT3 binding motifs in an area 5 kb upstream and
2 kb downstream of microRNAs.
In Situ Hybridization
Double-digoxigenin–labeled miRCURY Locked Nucleic
AcidDetection probe for the detection ofmiR-214 (38494-15;
Exiqon) by in situ hybridization was used as previously
described with modifications(13). Sections of control, ulcer-
ative colitis, and colorectal carcinomas were deparaffinized
with xylene (3 times for 5 minutes), followed by treatment
with serial dilutions of ethanol (3 times in 100%, twice
in 96%, and 3 times in 70%), and by 2 changes of Diethyl
pyrocarbonate–phosphate-buffered saline. Tissues thenwere
digested with proteinase K (15 mg/mL) for 30 minutes
at 37C and rinsed 3 times with Diethyl pyrocarbonate–
phosphate-buffered saline. Sections were dehydrated twice
with 70%, 96%, and 100% ethanol, air-dried, and hybridized
for 1 hour with the homo sapiens-miR-214 (40 nmol/L)
diluted in microRNA in situ hybridizatin buffer (90000; Exi-
qon, Woburn, MA) at 60C. After hybridization, sections were
rinsed twice with 5 standard saline citrate, twice with 1
standard saline citrate, and 3 timeswith 0.2 standard saline
citrate, for 5 minutes each, at 60C, and phosphate-buffered
saline. The slides were incubated with blocking solution
(11585762001; Sigma-Aldrich, Saint Louis, MO) for 15
minutes and then with anti-digoxigenin antibody (1:800) in
2% sheep serum (013-000-121; Jackson Immunoresearch,
West Grove, PA) blocking solution for 1 hour, at room tem-
perature. After 3 washes with phosphate-buffered saline,
0.1% Tween-20, slides were incubated with the AP substrate
buffer (nitro blue tetrazolium - 5-bromo-4-chloro-3-indolyl-
phosphate tablet [11697471001, Roche] in 10 mL 0.2 mmol/
L Levamisole [31742; Sigma-Aldrich]) for 2 hours at 30C in
the dark. The reaction was stopped with 2 washes of AP stop
solution (50 mmol/L Tris-HCl, 150 mmol/L NaCl, and 10
mmol/L KCl) and 2 washes with water. Tissues were coun-
terstained with Nuclear Fast Red (Sigma-Aldrich) for 1 min-
ute and rinsed with water. At the end, sections were
dehydrated twice with 70%, 96%, and 100% ethanol and
mounted with coverslips in Eukitt mounting medium
(361894G; VWR, Visalia, CA). Images were captured with a
Nikon 80i upright microscope equipped with a Nikon Digital
Sight DS-Fi1 (Nikon,Melville, NY) color camera, using theNIS-
Elements image acquisition software (Nikon). All images
were captured and processed using identical settings.
Immunohistochemistry
For tissue immunostaining for phospho–NF-kB,
phospho-Akt, and Ki67, formalin fixed paraffin embedded
sections of colonic tissues from azoxymethane-DSS mice
treated with the chemical miR-214 inhibitor or negative
control were deparaffinized with xylene (3  5 minutes)
followed by treatment with serial dilutions of ethanol
(100%, 100%, 95%, and 95%, 10 minutes each) and by 2
changes of ddH2O. Antigen unmasking was achieved by
boiling the slides (95C–99C) for 10 minutes, in 10 mmol/L
sodium citrate, at pH 6.0. Sections were rinsed 3 times with
ddH2O, immersed in 3% H2O2 for 20 minutes, washed twice
with distilled deionized water and once with Tris-buffered
saline and 0.1% Tween-20, and blocked for 1 hour with
blocking solution (5% normal goat serum [5425; Cell
Signaling Technology, Danvers, MA] in Tris-buffered saline
and 0.1% Tween-20). Phospho-P65 (Ser536) (SAB4300009;
Sigma-Aldrich), phospho-Akt (Ser473) (4060; Cell Signaling
Technology), and Ki67 (12202; Cell Signaling Technology)
antibodies were diluted 1:200, 1:50, and 1:400, respectively,
in Signal Stain antibody diluent (8112; Cell Signaling Tech-
nology) and incubated with the sections overnight at 4C.
After incubation with the antibodies, sections were washed
3 times, for 5 minutes each, with Tris-buffered saline and
0.1% Tween-20 and incubated for 1 hour at room temper-
ature with Signal Stain Boost (horseradish peroxidase, rab-
bit [8114], or horseradish peroxidase, mouse [8125]; Cell
Signaling Technology). Sections were washed 3 times, for 5
minutes each, with Tris-buffered saline and 0.1% Tween-20,
and stained with the 3,30-diaminobenzidine tetra hydro-
chloride Peroxidase Substrate Kit (SK-4100; Vector Labo-
ratories, Burlingame, CA) for 30 minutes, washed, and
counterstained with the hematoxylin QS (H-3404; Vector
Laboratories). Finally, tissues were dehydrated and moun-
ted in Eukitt medium. Microscope equipped with a Nikon
Digital Sight DS-Fi1 color camera, using the NIS-Elements
image acquisition software. All images were captured and
processed using identical settings.
Quantitative Real-Time PCR Analysis
Real-time PCR was performed to determine the expres-
sion levels of miR-214 in human colon carcinomas and tis-
sues. RNA was isolated, using TRIzol (15596-026;
Invitrogen, Carlsbad, CA). Reverse transcription was per-
formed using the Universal complementary DNA synthesis
kit (203300; Invitrogen). Real-time PCR was performed in
triplicate using the SYBR Green master mix (203450) and
primers for miR-214 (204510; Exiqon) in a CFX384 Real
Time PCR detection system (Bio-Rad, Hercules, CA). MIR214
expression levels were normalized to the levels of U6 small
nuclear RNA (203907; Exiqon).
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Real-time PCR was used to determine the expression
levels of PTEN and PDLIM2. Reverse transcription was
performed using the Retroscript Kit (AM1710; Applied
Biosystems, Foster City, CA). Real-time PCR was performed
using the IQ SYBR Green supermix (170-8882; Bio-Rad).
Glyceraldehyde-3-phosphate dehydrogenase and B-actin
were used as the internal control. The sequences of the
primers used were as follows: PTEN-F: 5’-cccagacatga-
cagccatc-3’; PTEN-R: 5’-tctgcaggaaatcccatagc-3’; PDLIM2-F:
5’-atggccacgattatgtctcc-3’; PDLIM2-R: 5’-gcccatcatggtgac-





Mouse studies were approved by the University of Cal-
ifornia Institutional Animal Care and Use Committee and
conformed to the US National Institutes of Health Guide for
the Care and Use of Laboratory Animals. The therapeutic
potential of the miR-214 inhibition was tested in a
mouse model of CAC. CAC is induced by administration of
12.5 mg/kg azoxymethane at day 1 followed by repeated
oral administration of 3% DSS on days 8, 29, and 50.
According to our treatment protocol, locked nucleic acid
miR-NC or locked nucleic acid miR-214 inhibitor were
administered intracolonically in azoxymethane-DSS–treated
mice on a weekly basis for 4 cycles (days 64, 70, 77, and 84).
For the inhibition of miR-214 expression, a locked
nucleic acid targeting the miR-214 sequence (5’-TGTCTG
TGCCTGCTG-3’) was used. The locked nucleic acid, often
referred to as inaccessible RNA, consists of modified RNA
nucleotides. The ribose moiety of a locked nucleic acid
nucleotide is modified with an extra bridge connecting the
2’ oxygen and 4’ carbon. The locked ribose conformation
enhances base stacking and backbone pre-organization.
This modification significantly increases the specificity and
hybridization properties with the target sequence (miR-
214). These oligonucleotides also are phosphorothioate-
modified. Phosphorothioate modifications provide protec-
tion against RNase activity and their lipophilicity contrib-
utes to enhanced tissue uptake. For intracolonic
administration animals were lightly anesthetized and a
polyethylene cannula (Intramedic PE-20 tubing; Becton
Dickinson, Parsippany, NJ) was inserted into the colon via
the anus. The locked nucleic acid miR-214 inhibitor was
diluted in phosphate-buffered saline (2.5 mg/mL) and in-
stilled into the colons using a syringe at a dose of 12 mg/kg,
whereas control animals were treated with locked nucleic
acid miR-NC (Exiqon, Danvers, MA). On day 91, the mice
were killed and the tumor burden was assessed.
Ex Vivo Biopsy Treatment
Fresh human colonic biopsy specimens from patients
with active disease, obtained by colonoscopy, were trans-
ported immediately to the laboratory in RPMI-1640 me-
dium on ice. Biopsy specimens were divided in 2 and
placed in organ culture dishes (48 wells) with RPMI-1640
medium containing 10% fetal calf serum. Colonic explant
cultures were treated with locked nucleic acid miR-214
inhibitor or locked nucleic acid miR-NC (25 mg/mL) for
18 hours at 37C with 95% O2 and 5% CO2. After culture
for 18 hours, tissue homogenates were subjected to RNA
isolation. RNAs were used for qPCR.
BioPlex Enzyme-Linked Immunosorbent Assays
We used a sandwich enzyme-linked immunosorbent
assay to assess the phosphorylation status of tyrosine 705 of
STAT3 protein in control colonic tissues and samples from
patients with ulcerative colitis and colitis-associated cancer,
the levels of cleaved caspase-3 in colonic tumors derived
from azoxymethane-DSS–treated mice, the phosphorylation
status of serine 473 of Akt protein, the phosphorylation
status of serine 536 of NF-kB protein, and the secretion of
IL6 in colonic cell lines. The data were analyzed in a BioPlex
FlexMap3D (Bio-Rad) analyzer using the BioPlex Manager
software.
Luciferase Assays
Colonic epithelial cells were transfected with a firefly
luciferase reporter gene construct containing the promoter
of MIR214. Cells were treated with IL6 for 24 hours after
transfection of the luciferase vector. Cell extracts were
prepared 24 hours later, and luciferase activity was
measured using the Dual Luciferase Reporter Assay System
(Promega, WI). For the 3’UTR assays, cells were transfected
with the reporter vectors carrying the 3’UTR of PTEN or
PDLIM2. At 24 hours they were transfected with miR-214
(or miR-scramble), and at 48 hours luciferase activity
was measured using the Dual Luciferase Reporter Assay
System.
Invasion Assays
We performed invasion assays in colonic epithelial cell
lines 24 hours after transfection with miR-214 or anti–miR-
214 or their respective controls. Invasion in Matrigel was
conducted using standardized conditions with BDBioCoat
growth factor reduced Matrigel invasion chambers (Phar-
Mingen, Franklin Lakes, NJ). Assays were conducted ac-
cording to the manufacturer’s protocol, using 2% fetal
bovine serum as a chemoattractant. Noninvading cells on
the top side of the membrane were removed whereas
invading cells were fixed and stained with 4’-6-diamidino-
2-phenylindole (Vector Laboratories, Inc) 16 hours after
seeding. In all assays, 10 fields per insert were scored and
the SE was calculated.
Colony Formation Assays
Colonic epithelial cells were transfected with miR-214 or
anti–miR-214 or their respective controls. Then, triplicate
samples of 105 cells from each cell line were mixed 4:1 (vol/
vol) with 2.0% agarose in growth medium for a final con-
centration of 0.4% agarose. The cell mixture was plated on
top of a solidified layer of 0.8% agarose in growth medium.
The number of colonies was counted after 6 days.
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Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as
described previously. Briefly, the chromatin fragments,
derived from untreated and IL6-treated colonic epithelial
cells, were immunoprecipitated with 6 ug of antibody
against STAT3. DNA extraction was performed using the
Qiagen Purification Kit (Qiagen, Valencia, CA). Real-time
PCR analysis was performed for the STAT3 binding site
in the MIR214 promoter using the following primers:
forward: 5’-CAAATTCCCCTCCCCTTTTA-3’ and reverse
5’-CAATCCTTGGACAATACTGTGTTT-3’ (product size:
111 bp).
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Supplementary Figure 1.miR-214 is up-regulated in the
colonic epithelium of human active UC samples. Quantifica-
tion of miR-214 staining using in situ hybridization. Scoring
was performed independently by 2 investigators, blind to the
sample IDs. N ¼ 4 per group.
Supplementary Figure 2.miR-214 expression in patients
with ulcerative colitis and Crohn’s disease. miR-214 expres-
sion, as assessed by qPCR, in UC patients does not correlate
to the (A) anatomic site of the colon or (B) sex, and does not
differ in CD patients based on (C) disease location or (D) sex.
Data are shown as the means ± SE.
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Supplementary Figure 6.miR-214 is up-regulated signifi-
cantly in colitis-associated colorectal cancer compared with
sporadic colorectal cancer. Quantification of miR-214 stain-
ing using in situ hybridization. Scoring was performed inde-
pendently by 2 investigators, blind to the sample IDs. N ¼ 4
for CRC and N ¼ 9 for CAC. ***P < .001.
Supplementary Figure 5.miR-214 levels are not de-
regulated in other inflammation-associated mouse models.
(A) 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colonic
inflammation does not deregulate miR-214 expression. Data
are shown as the means ± SE, in comparison with control
(TNBS-untreated) mice, 4 mice per group. (B) Polyp formation
in the APCmin mouse model does not involve changes in the
expression of miR-214. Data are shown as the means ± SE,
in comparison with control (no polyps) tissues, 5 tissues per
group.
Supplementary Figure 4. IL6 induces Akt phosphorylation in
colonocytes through miR-214. Effect of miR-214 inhibition on
IL6-induced Akt phosphorylation (S473), as assessed by
enzyme-linked immunosorbent assay. Data are shown as
the means ± SE. **P < .01, ***P < .001 in comparison with
untreated cells, #P< .001 in comparison with negative control
(NC) miR-treated cells, Student t test.
Supplementary Figure 3.miR-214 regulates the expression
of IL6 in colonic epithelial cells. Effect of miR-214 on the
expression of IL6 in NCM460 cells, as assessed by qPCR.
Data are shown as the means ± SE. ***P < .001 in compar-
ison with untreated and control (scramble) miR-treated cells,
Student t test.
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Supplementary Figure 8. IL6 suppresses the expression of
PDLIM2 and PTEN in colon cancer cells through miR-214.
Effects of IL6 and inhibition of miR-214 on the expression
of (A) PDLIM2 and (B) PTEN mRNA, as assessed by qPCR, in
HCT116 and HT29 cells. Data are shown as the means ± SE.
***P < .001 in comparison with untreated cells; @P < .01 in
comparison with the anti–miR-negative control (NC)-treated
cells, Student t test.
Supplementary Figure 7.miR-214 induces the tumorigenic
potential of colon cancer cells and mediates the tumorigenic
effects of IL6. miR-214 overexpression enhances the tumor-
igenic potential, whereas miR-214 inhibition reverses
the tumorigenic effects of IL6, on colon cancer cells. Effects
of miR-214 overexpression and miR-214 inhibition on
IL6-induced (A) colony formation in soft agar, and (B) invasion
of SW480 cells. Data are shown as the means ± SE.
**P < .01, ***P < .001 in comparison with untreated cells and
control (miR-scramble)-treated cells. #P < .001 in comparison
with anti–miR-negative control (NC)-treated cells, Student
t test.
992.e6 Polytarchou et al Gastroenterology Vol. 149, No. 4
Supplementary Figure 11.MiR-214 regulates the expression
of PDLIM2 and PTEN in colon cancer cells. Effects of miR-
214 on the levels of PDLIM2 and PTEN mRNA in HCT116
cells, as assessed by qPCR. ***P < .001 in comparison with
untreated and control (pre–miR-C)-treated cells, Student t
test.
Supplementary Figure 10.MiR-214 regulates the phos-
phorylation of NF-kB in colon cancer cells. Effects of miR-214
on the levels of pNF-kB (S536) in HCT116 cells, as assessed
by enzyme-linked immunosorbent assay. Data are shown as
the mean ± SE. ***P < .001 in comparison with untreated and
control (pre–miR-C)-treated cells, Student t test.
Supplementary Figure 9. IL6 induces the phosphorylation of
Akt in colon cancer cells through miR-214. Effect of miR-214
inhibition (as–miR-214) on IL6-induced Akt phosphorylation
(S473), as assessed by enzyme-linked immunosorbent assay.
Data are shown as the means ± SE. **P < .01, ***P < .001 in
comparison with untreated cells; #P < .001 in comparison
with control (as–miR-NC)-treated cells, Student t test. NC,
negative control.
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Supplementary Figure 13. The therapeutic protocol applied
on the azoxymethane (AOM)-DSS mouse model. To address
the therapeutic potential of miR-214 inhibition we used a
mouse model of colitis-associated colorectal cancer. In this
model colorectal cancer was induced by administration of
AOM followed by repeated oral administration of DSS.
Chemical microRNA negative control (miR-NC) or miR-214
inhibitor were administered intracolonically in AOM-
DSS–treated mice on a weekly basis for 4 cycles. On day 91,
the mice were killed and the tumor burden was assessed.
Supplementary Figure 12. PDLIM2 and PTEN expression is
down-regulated in colon tumors from CAC patients. PDLIM2
and PTEN mRNA levels in CAC and control colonic tissues
was assessed by qPCR.
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Supplementary Table 2.Characteristics of Patients Analyzed for miR-214 Expression
Groups Control UC CD IBS CAC CRC
Patients, n 107 120 60 22 32 60
Age, y
Median 42 39.5 33 38.5 55.5 70
Range 16–80 20–72 17–74 18–55 25–82 31–91
Missing data 9 10
P value NS NS NS a a,b
Sex, n (%)
Female 31 (29) 41 (34) 15 (25) 11 (50) 18 (56) 28 (47)
Male 57 (53) 44 (37) 29 (48) 11 (50) 14 (44) 32 (53)
Missing data 19 (18) 35 (29) 16 (27)
P value NS NS NS NS NS (0.192)
Disease duration 11 (0.3–30)
TNM stage, n (%)
I 6 (19) 13 (22)
II 16 (50) 19 (32)
III 7 (22) 18 (30)
IV 3 (9) 10 (17)
P value NS (0.390)
IBS, irritable bowel syndrome.
aP < .001 between groups (Kruskall–Wallis test).
bP < .001 in comparison with CAC (Wilcoxon 2-sample test).
Supplementary Table 1.Cohorts of Patients Analyzed for
miR-214 Expression
Cohorts Control UC CD IBS CAC CRC
UCLA 43 18 24 22 6 18
Leiden 52 63 13 22 27
Origene 12 39 23 4 15
Total patients 107 120 60 22 32 60
IBS, irritable bowel syndrome; UCLA, University of California
at Los Angeles.
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Supplementary Table 3.Expression of miR-214 Targets vs Control (miR-Scramble) in Colonic Epithelial Cells
Symbol ID Name Fold change P
ABR 29 Active BCR-related 2.16 a
ACER3 55331 Alkaline ceramidase 3 1.67 a
ADSS 159 Adenylosuccinate synthase 3.57 a
AP3B1 8546 Adaptor-related protein complex 3, b 1 subunit 1.53 b
ARPC5L 81873 Actin-related protein 2/3 complex, subunit 5-like 2.07 a
BAZ2A 11176 Bromodomain adjacent to zinc finger domain, 2A 1.79 a
BRPF3 27154 Bromodomain and PHD finger containing, 3 1.58 a
CD151 977 CD151 molecule (Raph blood group) 2.62 a
CDC25B 994 Cell division cycle 25 homolog B (S pombe) 1.90 a
CDIPT 10423 CDP-diacylglycerol–inositol 3-phosphatidyltransferase 1.79 a
CEP85 64793 Centrosomal protein 85 kilodaltons 1.57 a
CHMP4B 128866 Charged multivesicular body protein 4B 1.69 a
CPEB4 80315 Cytoplasmic polyadenylation element binding protein 4 1.92 a
CTDSP1 58190 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide
A) small phosphatase 1
1.70 a
CTSS 1520 Cathepsin S 2.12 a
DNAJC5 80331 DnaJ (Hsp40) homolog, subfamily C, member 5 1.59 a
F8 2157 Coagulation factor VIII, procoagulant component 1.62 a
FAM134A 79137 Family with sequence similarity 134, member A 3.66 a




GLI3 2737 GLI family zinc finger 3 2.13 a
HMG20A 10363 High-mobility group 20A 1.75 a
IGSF3 3321 Immunoglobulin superfamily, member 3 1.64 a
INO80C 125476 INO80 complex subunit C 2.40 a
INTS2 57508 Integrator complex subunit 2 1.61 a
IPO11 51194 Importin 11 2.06 a
ITCH 83737 Itchy E3 ubiquitin protein ligase 1.67 a
KLHDC3 116138 Kelch domain containing 3 1.56 a
KLK10 5655 Kallikrein-related peptidase 10 1.71 a
LAPTM4B 55353 Lysosomal protein transmembrane 4b 1.84 a
LARP1 23367 La ribonucleoprotein domain family, member 1 2.12 a
LEPROTL1 23484 Leptin receptor overlapping transcript-like 1 2.24 a
MED19 219541 Mediator complex subunit 19 1.90 a
MTM1 4534 Myotubularin 1 1.56 a
NAA15 80155 N(a)-acetyltransferase 15, NatA auxiliary subunit 2.94 a
OTUB1 55611 OTU domain, ubiquitin aldehyde binding 1 1.59 a
PAPD5 64282 PAP-associated domain containing 5 1.73 a
PDLIM2 64236 PDZ and LIM domain 2 (mystique) 3.37 a
PGGT1B 5229 PGGT1B 2.25 a
PLA2G15 23659 Phospholipase A2, group XV 1.66 a
PLK4 10733 Polo-like kinase 4 1.55 a
POLE3 54107 Polo-like kinase 4 1.55 a
PPP2CB 5516 Protein phosphatase 2, catalytic subunit, b isozyme 1.68 a
PPP6C 5537 Protein phosphatase 6, catalytic subunit 1.72 a
PSMD10 5716 Proteasome (prosome, macropain) 26S subunit,
non–adenosine triphosphatase, 10
3.19 a
PTEN 5728 Phosphatase and tensin homolog 2.47 a
RAB14 51552 RAB14, member RAS oncogene family 2.54 a
RASSF5 83593 Ras association (RalGDS/AF-6) domain family member 5 1.52 a
RBM22 55696 RNA binding motif protein 22 2.46 a
RNF115 27246 Ring finger protein 115 1.71 a
RPIA 22934 Ribose 5-phosphate isomerase A 1.57 a
SEC24C 9632 SEC24 family, member C (S cerevisiae) 1.95 a
SLC25A44 9673 Solute carrier family 25, member 44 2.02 a
SLC7A8 23428 Solute carrier family 7 (amino acid transporter light chain,
L system), member 8
1.75 a
SMG5 23381 Smg-5 homolog, nonsense-mediated mRNA decay factor (C elegans) 1.81 a
SNX12 29934 Sorting nexin 12 3.38 a
SYS1 90196 SYS1 Golgi-localized integral membrane protein homolog (S cerevisiae) 1.55 a
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Supplementary Table 3.Continued
Symbol ID Name Fold change P
TAF15 8148 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated
factor, 68 kilodaltons
1.72 a
TBC1D17 79735 TBC1 domain family, member 17 1.56 b
TBPL1 9519 TBP-like 1 1.63 a
TFAP2C 7022 Transcription factor AP-2 g (activating enhancer binding protein 2 g) 1.59 a
TGOLN2 10618 Trans-golgi network protein 2 1.96 a
TMEM135 65084 Transmembrane protein 135 1.52 a
TMEM245 23731 Transmembrane protein 245 1.53 a
TMEM161B 153396 Transmembrane protein 161B 2.25 a
TMTC4 84899 Transmembrane and tetratricopeptide repeat containing 4 2.18 a
TPP1 1200 Tripeptidyl peptidase I 2.83 a
UBE2B 7320 Ubiquitin-conjugating enzyme E2B 1.94 a
UBE2H 7328 Ubiquitin-conjugating enzyme E2H 1.99 a
USP3 9960 Ubiquitin-specific peptidase 3 1.55 a
VAMP5 10791 Vesicle-associated membrane protein 5 1.62 a
C elegans, caenorhabditis elegans; S cerevisiae, saccharomyces cerevisiae; S pombe, saccharomyces pombe.
aP < .001 in comparison with control (miR-scramble)-treated cells.
bP < .01.
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